Диссертация (1140680), страница 24
Текст из файла (страница 24)
– P. 885-97.117. Chen, C.H. Outcome of GreenLight HPS laser therapy in surgically highrisk patients: [Electronic resource] / С.Н. Chen, S.E. Lin, P.H. Chiang // Lasers inMedical Science. – 2013. – Vol. 28, iss. 5. – P. 1297-1303. – Mode of access:https://link.springer.com/article/10.1007/s10103-012-1234-9. – Date of access:10.12.2017118. Clifford, G.M.
Medical therapy for benign prostatic hyperplasia: a review ofthe literature / G.M. Clifford, R.D. Farmer // European Urology. – 2000. – Vol. 38,№ 1. – P. 2-19.119. Complications of transurethral resection of the prostate (TURP)-incidence,management, and prevention / J. Rassweiler, D. Teber, R. Kuntz, R. Hofmann //European Urology. – 2006.
– Vol. 50, № 5. – P. 969-979.120. Critical review of lasers in benign prostatic hyperplasia (BPH) / S. Gravas[et al.] // British Journal of Urology. – 2011. – Vol. 107, № 7. – Р. 1030-1043.121. CUA guideline: Diagnosis and treatment of interstitial cystitis bladder painsyndrome : [Electronic resource] / Ashley Cox [et al.]. – 2016.
– 155 c. – Mode ofaccess: http://www.cua.org/themes/web/assets/files/3786v3.pdf. – Date of access:10.12.2017.122. Dajusta, D. Dextranomer/hyaluronic acid bladder neck injection forpersistent outlet incompetency after sling procedures in children with neurogenicurinary incontinence / D. Dajusta, P. Gargollo, W. Snodgrass // Journal ofPediatric Urology. – 2013.
– Vol. 9, № 3. – P. 278-282.123. Damiano, R. Prevention of recurrent urinary tract infections by intravesicaladministration of hyaluronic acid and chondroitin sulphate: A placebo-controlledrandomised trial / R. Damiano, G. Quarto, I. Bava // European Urology. – 2011. –Vol. 59, № 4. – P. 645-651.155124. Damiano, R. The role of sodium hyaluronate and sodium chondroitinsulphate in the management of bladder disease / R. Damiano, A. Cicione //Therapeutic Advances in Urology. – 2011. – Vol. 3, № 5.
– P. 223-32.125. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome:[Electronic resource] / P. M. Hanno [et al.] // The Journal of Urology. – 2014. –Vol.193,iss.5.–P.–1545-1553.Modeofaccess:http://www.auanet.org/documents/education/clinical-guidance/IC-Bladder-PainSyndrome-Revised.pdf .
– Date of access: 10.12.2017.126. EAU Guidelines on the Assessment ofNon-neurogenic Male LowerUrinary Tract Simptoms including Benign Prostatic Obstruction / C. Gratzke [etal.] // European Urology. – 2015. – Vol. 67, № 6. – P. 1099-1109.127. EAU guidelines on the treatment and follow-up of nonneurogenic malelower urinary tract symptoms including benign prostatic obstruction / M. Oelke [etal.] // European Urology. – 2013. – Vol.
64, № 1. – P. 118–140.128. Effects of serum PSA on efficacy of tolterodine extended release with orwithout tamsulosin in men with LUTS, including OAB / C.G. Roehrborn [et al.] //Urology. – 2008. – Vol. 72, № 5. – P. 1061–1067.129. Efficacy and safety of bipolar plasma vaporization of the prostate with"button-type" electrode compared with transurethral resection of prostate forbenign prostatic hyperplasia / S.Y.
Zhang [et al.] // Chinese Medical Journal. –2012. – Vol. 125, № 21. – P. 3811-3814.130. Efficacy and safety of extended-release oxybutynin in combination withtamsulosin for treatment of lower urinary tract symptoms in men: randomized,double-blind, placebo-controlled study / S.A. MacDiarmid [et al.] // Mayo ClinicProceedings. – 2008. – Vol. 83, № 9. – P. 1002-1010.131. Efficiacy of interstitial Cystitis treatment: a review / G.
Karsenty, W.AlTaweel, S. Hajebrahimi, J. Corcos // EAU-EBU update. – 2006. – Vol. 4, iss. 2.– Р. 47-61 – (series 4).132. Embaron, M. Benign prostate hyperplasia: Social impact and patient'sperspective / M. Embaron // European Urology. – 2008. – Vol. 5, № 11 – P. 45-56.156133. Fotso Kamdem, A. Long-term incidence of febrile UTI after DxHAtreatment of VUR / A. Fotso Kamdem , G.
Galli , D. Aubert // Journal of PediatricUrology. – 2014. – Vol. 10, № 5. – P. 56-61.134. Gacci, M.A. Systematic review and meta-analysis on the use ofphosphodiesterase 5 inhibitors alone or in combination with alpha-blockers forlower urinary tract symptoms due to benign prostatic hyperplasia / M. Gacci [et al.]// European Urology.
– 2012. – Vol. 61, № 5. – P. 994–1003.135. Guidelines for the management of BPH. Update / J.C. Nickel [et al.] //Canadian Urological Association Journal. – 2010. –Vol. 4, № 5. – Р. 310–316.136. Guidelines on urological infections. 2015: [Electronic resource] / EuropeanAssociation of Urology. – Mode of access: http://uroweb.org/guideline/urologicalinfections. – Date of access: 10.12.2017.137. Homma, Y. Clinical guidelines for interstitial cystitis and hypersensitivebladder syndrome: Guidelines (Review) / Y. Homma [et al.] // InternationalJournal of Urology.
– 2009. – Vol. 16, № 7. – P. 597-615.138. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome / C.R.Riedl [et al.] // Int Urogynecol J Pelvic Floor Dysfunct. – 2008. – Vol. 19, № 5. –P. 717-721.139. Hyaluronic acid decreases IL-6 and IL-8 secretion and permeability in aninflammatory model of interstitial cystitis / P. Rooney [et al.] // Acta Biomater. –2015. – № 19. – 66-75.140.
Impact of intravesical hyaluronic acid and chondroitin sulfate on bladderpain syndrome/interstitial cystitis / D. Porru [et al.] // Int. Urogynecol J. – 2012. –№ 23. – 1193-1199.141. Inflammation, apoptosis and BPH: What is the evidens? / G. Novara [et al.]// European Urology Supplements. – 2006. – Vol. 12, № 5. – P. 401-409.142. Intravesical Alkalinized Lidocaine (PDS597) Offers Sustained Relief fromSymptoms of Interstitial Cystitis and Painful Bladder Syndrome / J.C.
Nickel [etal.] // British Journal of Urology. – 2009. – Vol. 103, № 7. – P. 910-918.143. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis /157A. Morales [et al.] // Journal of Urology. – 1996. – Vol. 156, № 8 – P. 45.144. Intravesical hyaluroni-dase causes chronic cystitis in a rat model: a potentialmodel of bladder pain syndrome/interstitial cystitis / Y.S. Ly [et al.] // InternationalJournal of Urology. – 2014. – Vol. 21, № 6. – P. 601-607.145. Is there evidence of a relationship between benign prostatic hyperplasia andprostate cancer? Findings of a literature review / A. Alcaraz [et al.] // EuropeanUrology. – 2009.
– Vol. 55, № 4. – P. 864-73.146. Kaplan, S.A. Tolterodine extended release attenuates lower urinary tractsymptoms in men with benign prostatic hyperplasia / S.A. Kaplan, K. Walmsley,A.E. Te // Journal of Urology – 2005. – Vol. 174, № 6. – P. 2273–2275.147. Konservative Therapie der postoperativen Harninkontinenz des Mannes /J.N. Nyarangi-Dix [et al.] // Urologе. – 2010. – Vol. 49, № 9 – P.
408-503.148. Kuo, H. C. Analysis of the pathophysiology of lower urinary tract symptomsin patients after prostatectomy / H. C. Kuo // International Journal of Urology. –2002. – Vol. 68, № 2. – P. 99-104.149. Mamoulakis, C. Bipolar versus monopolar transurethral resection of theprostate: a systematic review and meta-analysis of randomised controlled trials /Mamoulakis C., Ubbink D.T., de la Rosette J.
// European Urology. – 2009. – Vol.56, № 5. – P. 798–809.150. McVary, K.T. BPH: epidemiology and comorbidities / K.T. McVary // Am JManag Care. – 2006. – № 12. – P. 122–128.151. Meta-analysis oftransurethrаlfunctionalproceduresforoutcomeslowerurinaryandcomplicationsfollowingtract symptoms resulting frombenign prostatic enlargement / S.A. Ahyai [et al.] // European Urology. – 2010. –Vol. 58, № 3. – P. 384–397.152.
Moldwin R. Guidelines for Intravesical Drug Instillation: [Electronicresource] / North shore long island jewish health sytem; Smith Institute forurology. –International Painful Bladder Foundation, 2009. – 3 p. – Mode of access:http://www.painful-bladder.org/pdf/guidelines%20for%20intravesical%20drug%20instillation_smith%20instit158ute.pdf. – Date of access: 10.12.2017.153.
Monotherapy with tadalafil or tamsulosin similarly improved lower urinarytract symptoms suggestive of benign prostatic hyperplasia in an international,randomised, parallel, placebo-controlled clinical trial / M. Oelke [et al.] //European Urology. – 2012. – Vol. 61, № 5. – P. 917–925.154. Naftopidil and propiverine hydrochloride for treatment of male lowerurinary tract symptoms suggestive of benign prostatic hyperplasia and concomitantoveractive bladder: a prospective randomized controlled study / T.
Yokoyama [etal.] // Scandinavian Journal Of Urology And Nephrology. – 2009. – Vol. 43, № 4.– P. 307–314.155. Nakagava, K. A new minimally invasive medical treatment for prostatichyperplasia: its current situation and actual practice of the operation; TUEB / K.Nakagava // Urology View. – 2007. – Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
